Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.
Cyclo Therapeutics, Inc. (CYTH) is a clinical-stage biotechnology company dedicated to developing cyclodextrin-based treatments for neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company was originally organized in 1990 and began operations in 1992. Over the years, Cyclo Therapeutics has evolved into a holding company operating under various subsidiaries, including CTD, Inc.; Nanosonic Products, Inc.; Sphingo Biotech, Inc.; and Ferrazo Environmental Technologies, Inc.
The company's flagship product, Trappsol Cyclo, is at the forefront of its clinical trials for NPC treatment. Cyclo Therapeutics is committed to advancing this promising treatment through various phases of clinical testing, aiming to bring it to market to provide relief for NPC patients.
In addition to its focus on rare diseases, Cyclo Therapeutics generates revenue from the sale of cyclodextrins and related products to pharmaceutical and nutritional industries. Key products include Trappsol HPB and Trappsol Fine Chemical, which are widely used in various industries.
Recent Achievements:
- Successfully completed Phase I clinical trials for Trappsol Cyclo.
- Expanded partnerships with pharmaceutical companies for cyclodextrin-based product development.
- Enhanced research and development capabilities through strategic collaborations.
Cyclo Therapeutics' commitment to innovation and its strategic approach to product development and commercialization have positioned it as a significant player in the biotechnology sector. The company remains focused on its mission to develop effective treatments for rare and neurodegenerative diseases.
Cyclo Therapeutics (NASDAQ: CYTH) presented its ongoing pivotal Phase 3 study, TransportNPC™, at the 18th Annual WORLD Symposium 2022. The trial focuses on the efficacy of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, with results expected in 96 weeks. Designed in collaboration with regulatory bodies and experts, the study aims to enroll at least 93 patients across 23 centers in 9 countries. Cyclo Therapeutics has received various designations for Trappsol® Cyclo™, highlighting its commitment to addressing unmet medical needs in this patient population.
Cyclo Therapeutics (NASDAQ: CYTH) announced the formation of a Global Steering Committee to oversee its pivotal Phase 3 study, TransportNPC™, for treating Niemann-Pick Disease Type C (NPC). This multicenter trial aims to evaluate the safety and efficacy of Trappsol® Cyclo™. Preliminary data suggests potential for disease stabilization with home-based infusions. The study will enroll at least 93 pediatric and adult patients across 9 countries, featuring a randomized, placebo-controlled design with a 96-week duration and an interim analysis at 48 weeks.
Cyclo Therapeutics (Nasdaq: CYTH) announced a live video webcast presentation on January 27, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO N. Scott Fine will present followed by a moderated discussion and Q&A session, allowing live and pre-submitted questions from investors. A webcast replay will be available for one year after the event. Cyclo Therapeutics is focused on developing treatments for rare diseases, including Niemann-Pick Disease Type C, and is preparing for trials involving Alzheimer's Disease.
Cyclo Therapeutics has appointed Dr. Caroline Hastings as Global Principal Investigator for the pivotal Phase 3 study, TransportNPC™, aimed at treating Niemann-Pick Disease Type C1. The study, currently enrolling patients, evaluates the efficacy of Trappsol® Cyclo™ over 96 weeks across 23 centers in 9 countries. Preliminary data show promising results, suggesting disease stabilization and safety over two years. The company also received positive feedback from the EMA regarding its pediatric investigation plan.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that the FDA has approved its IND application to proceed with a Phase 2 study of Trappsol® Cyclo™ for early Alzheimer’s disease. The company expressed satisfaction with the FDA's feedback and aims to address the critical need for effective treatments. Trappsol® Cyclo™ has demonstrated potential in managing cholesterol transport, which is linked to Alzheimer’s pathology. Cyclo Therapeutics is also advancing its treatment for Niemann-Pick disease Type C1, reinforcing its commitment to neurodegenerative disease therapies.
Cyclo Therapeutics has priced its public offering of 1,950,000 shares at $6.00 per share, expected to raise $11.7 million in gross proceeds. The underwriter, Maxim Group LLC, has a 45-day option to purchase an additional 292,500 shares. This offering is made under an effective shelf registration statement with the SEC. The funds will support the company's clinical developments, including trials for Niemann-Pick Disease Type C and potential Alzheimer's applications.
Cyclo Therapeutics has initiated an underwritten public offering of its common stock, with details subject to market conditions. The offering is conducted by Maxim Group LLC as the sole book-running manager and will follow an effective shelf registration statement filed with the SEC. The company aims to secure funding to support its clinical trials for Trappsol® Cyclo™, which is currently involved in four trials for Niemann-Pick Disease Type C and is exploring further applications in Alzheimer’s Disease.
Cyclo Therapeutics (NASDAQ: CYTH) has submitted an initial investigational new drug (IND) application to the FDA for Trappsol® Cyclo™, targeting early Alzheimer’s Disease. The Phase 2 study design is based on clinical data from Niemann-Pick Disease Type C and 18 months' experience with a late-onset Alzheimer’s patient. The drug aims to address cholesterol accumulation and oxidative stress, conditions shared in both diseases. The company highlights significant unmet needs in Alzheimer’s treatment, positioning Trappsol® Cyclo™ as a potential solution.
Cyclo Therapeutics (Nasdaq: CYTH) reported its Q3 2021 financial results, highlighting ongoing progress in its pivotal Phase 3 study, TransportNPC™, for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1. The company appointed Lise Lund Kjems as Chief Medical Officer and Cynthia A. Lemere as Senior Advisor for Alzheimer’s. Q3 net loss was approximately $3.8 million with R&D expenses increasing by 69% to $1.8 million. Cyclo Therapeutics holds approximately $8.4 million in cash as of the end of the quarter, anticipating further R&D expenses as clinical trials progress.
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) has announced a Virtual Investor Roundtable Event on November 16, 2021, at 11:00 AM ET. CEO
Cyclo Therapeutics focuses on developing medicines for rare diseases, including Niemann-Pick Disease Type C.
FAQ
What is the current stock price of Cyclo Therapeutics (CYTH)?
What is the market cap of Cyclo Therapeutics (CYTH)?
What does Cyclo Therapeutics, Inc. specialize in?
What is Trappsol Cyclo?
When was Cyclo Therapeutics founded?
What are some of Cyclo Therapeutics' key products?
What are the subsidiaries of Cyclo Therapeutics?
Where does Cyclo Therapeutics generate its revenue from?
What recent achievements has Cyclo Therapeutics accomplished?
What is the focus of Cyclo Therapeutics' research?
How does Cyclo Therapeutics contribute to healthcare?
What is the significance of cyclodextrins in Cyclo Therapeutics' products?
